Successful Urine Multiplex Bead Assay to Measure Lupus Nephritis Activity

Ellen M. Cody¹, Michael R. Bennett¹,², Gaurav Gulati³, Qing Ma⁴, Mekibib Altaye⁵, Prasad Devarajan¹,² and Hermine I. Brunner²,⁶

¹Department of Pediatric Nephrology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA; ²Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA; ³Division of Immunology, Allergy and Rheumatology, Department of Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA; ⁴Nephrology and Hypertension Clinical Laboratory, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA; ⁵Division of Biostatistics and Epidemiology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA; and ⁶Division of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA

Introduction: Lupus nephritis (LN) confers a poor prognosis, mainly from lack of effective laboratory tests to diagnose and to evaluate therapies. We have previously shown that a set of 6 urinary biomarkers (NGAL, KIM-1, MCP-1, adiponectin, hemopexin, and ceruloplasmin) are highly sensitive and specific to identify adult and pediatric patients with active LN using renal biopsy as reference standard. Using these combinatorial urinary biomarkers, the Renal Activity Score for Lupus (RAIL) score was established, with biomarkers measured by enzyme-linked immunosorbent assay (ELISA). To enhance clinical utility of the biomarkers and RAIL, we tested the performance of RAIL with biomarkers measured by ELISA to that of biomarkers measured by the bead multiplex method, hypothesizing that the multiplex bead method would be comparable.

Methods: Spot urine samples (n = 341) of 46 patients aged 20 to 73 years with or without LN were used. Samples were assayed both by ELISA and multiplex using LUMINEX. RAIL scores and biomarker quantities were assessed for agreement with intraassay correlation coefficients and compared using Bland–Altman and regression.

Results: Biomarker measurement by LUMINEX was successful for NGAL, KIM-1, MCP-1, and adiponectin, but not for ceruloplasmin and hemopexin. There was good agreement of the RAIL obtained from these 4 biomarkers, irrespective of assay method (intraclass correlation coefficient [ICC] = 0.78, 95% confidence interval [CI] = 0.78–0.82). The RAIL scores from 4 biomarkers further correlated with those when considering all 6 biomarkers (ICC = 0.97, 95% CI = 0.96–0.98).

Conclusion: The LUMINEX platform allows for the convenient and simultaneous measurement of 4 RAIL biomarkers. RAIL scores considering only these 4 biomarkers may be sufficient to accurately capture LN activity.

Kidney Int Rep (2021) 6, 1949–1960; https://doi.org/10.1016/j.ekir.2021.04.016
KEYWORDS: ELISA; lupus; nephritis; multiplex; RAIL; SLE
© 2021 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
inflammation and response to therapy over time. Hence, there is a crucial need for new diagnostic tests that noninvasively, accurately, and rapidly detect response to treatment and predict LN flares.

We have previously described and validated a panel of 6 urinary biomarkers, consisting of neutrophil gelatinase–associated lipocalin (NGAL), monocyte chemoattractant protein–1 (MCP-1/CCL2), kidney injury molecule–1 (KIM-1), ceruloplasmin, adiponectin, and hemopexin. Considering the concentrations of all 6 biomarkers, the Renal Activity Index for Lupus (RAIL) can be calculated, on which a higher score reflects high renal inflammation on biopsy. We have shown that the RAIL is >90% accurate in detecting LN activity histologic activity measures from kidney biopsy as reference standard. This work has been replicated in both pediatric and adult patients and to identify those with and without LN. Furthermore, changes in the RAIL score precede clinically observed worsening and response to LN therapy for up to 3 months. The RAIL biomarkers in all prior research were assayed using individual enzyme-linked immunosorbent assays (ELISAs). This can be time consuming, laborious, and can make ad hoc testing of individual patients cumbersome and costly. As the calculation of the RAIL requires knowledge of the quantities of 6 biomarkers, a convenient multiplex assay will be advantageous, preferable, and clinically actionable. A multiplexed reaction also allows multiple biomarkers to be assayed at the same time, often requiring a smaller amount of sample. To move the RAIL score toward clinical usability and efficacy, we compared the urinary biomarkers via the original ELISA assay to the multiplex platform to assess correlation between the two. We hypothesized that the multiplex platform would be suitable to assay biomarker concentrations when compared with ELISA measurements as reference standard. We also hypothesized that the RAIL score composed of only 4 biomarkers (calculated with NGAL, MCP-1, KIM-1, and adiponectin), would result in similar detection of high LN activity when compared to the original RAIL score that considers 6 biomarkers.

**Materials and Methods**

**Patients**

This was a retrospective analysis performed on banked urine samples that were obtained from 46 adults who participated in a clinical trial sponsored by Medimmune LLC. Exclusion criteria for this study included active severe SLE-driven renal disease or unstable renal disease prior to screening. They had completed induction therapy and were on stable steroid doses. However, there were longitudinal samples collected and they were monitored for drug treatment efficacy or failure, including LN flare. Because of disease heterogeneity, kidney biopsy samples were not collected.

Besides random spot urine samples from these patients with or without LN, we obtained patient demographics and the results of routine laboratory testing. The SLE disease activity was measured according to the British Isles Lupus Assessment Group (BILAG). The Renal BILAG scores were converted from the letter grading (A–E), with A denoting worse disease, to numeric (A = 12, B = 8, C = 1, D and E = 0) for ease of data analysis, as previously described. The study was approved by the Institutional Review Board of the Cincinnati Children’s Hospital Medical Center (CCHMC) and the institutional review boards of all other participating centers, with informed consent obtained prior to any study-related procedures (IRB # 2017-0585).

**Sample Storage and Processing**

Following sample collection, urinary specimens were stored at 4 °C within 1 hour of collection. They were then spun down and frozen at −80 °C. The urine underwent a single thaw cycle prior to processing. Urine biomarkers were quantified using commercial ELISA kits and multiplex platform. The following biomarkers were measured: adiponectin, ceruloplasmin, KIM-1, MCP-1, NGAL, and hemopexin.

**ELISA**

Unless stated otherwise, biomarkers were quantified using commercial ELISA kits as per the manufacturer’s instructions, and a 4-parameter logistic curve was used to fit the standard curve. Human NGAL was performed using a commercially available assay (BIOPORTO, Hellerup, Denmark, catalog KIT 036RUO); starting dilution 1:500, and the lower limit of detection is 4 pg/ml. Intra- and interassay coefficients of variation were 1.0% and 9.1% respectively. The Human KIM-1 ELISA assay was constructed using commercially available reagents (Duoset DY, R&D Systems, Minneapolis, MN; DY1750B) as described previously (starting dilution 1:1, with a lower limit of detection of 50 pg/ml). Intra- and inter-assay coefficients of variation were 2.0% and 7.8%, respectively. Human MCP-1 was measured via ELISA (R&D Systems, Minneapolis, MN; DCP00, starting dilution of 1:1, with a lower limit of detection 31.2 pg/ml. Intra-assay and interassay were 5.0% and 5.9% respectively. Human adiponectin was measured by commercially available ELISA kit (R&D Systems, Minneapolis, MN; DRP300), diluted 1:1, with a lower limit of detection 3.9 ng/ml. Intra-assay and inter-assay coefficients of variation were 3.7% and 6.8%,
respectively. Human ceruloplasmin was measured by ELISA Kit (Assaypro LLC, St. Charles, MO; EC4201-1), 1:10-20 dilution, with a lower limit of detection 0.156 ng/ml. Intra-assay and inter-assay were 4.1% and 7.1%, respectively. Hemopexin was measured by commercially available ELISA kit (Assaypro LLC, St. Charles, MO; EH2001-1), 1:10 dilution, with a lower limit of detection 6.25 ng/ml. Intra-assay and inter-assay coefficients of variation were 4.7% and 9.2%, respectively.

**Multiplex Platform**

Biomarkers using multiplex platform (MPL) assays were run during a different freeze–thaw cycle on the same urinary specimens. Multiplex measurements were performed using the Luminex MAGPIX Platform. The following multiplex kits were used: MCP-1 (R&D Systems LUHM279), NGAL (R&D Systems, LHK1757), Adiponectin (Invitrogen, EPX01A-12032-901), KIM-1 (made in-house using R&D kit DY1750), Human Hemopexin (Abcam, #51515), and Human Ceruloplasmin (Assaypro, Cat. #11261-05011).

**Statistical Analysis**

The 2 methodologies, ELISA and multiplex assays, were compared for each of the urinary biomarkers. The urinary biomarkers were then applied to the Adult RAIL (A-RAIL) algorithm, using the following formula:

\[ \text{RAIL} = 5.05 - 0.56\times\text{NGAL} + 0.12\times\text{MCP-1} + 0.88\times\text{Adiponectin} + 0.01\times\text{Hemopexin} - 0.02\times\text{KIM-1} - 0.29\times\text{Ceruloplasmin}. \]

This algorithm has been validated for adults, where a result of greater than or equal to 1.92 correlates with high levels of renal inflammation on biopsy, meaning a NIH-AI score >10.10

The reliability or agreement of the individual urinary biomarkers as well as the RAIL score obtained from each methodology were assessed using intraclass correlation coefficients (ICC) obtained from a 2-way mixed effects model. An ICC of <0.5 represents poor reliability, between 0.5 and 0.75 represents moderate reliability, 0.75 to 0.9 indicates good reliability, and >0.9 indicates excellent reliability.16

Although ICC is the primary analytical method for assessing reliability, it is a summary measure. To display individual data points and their relationship with each other, we also report correlations (scatter plot) and Bland–Altman plots. A Pearson correlation coefficient was obtained along the scatter plot, with r of 0.1 to 0.39 representing weak correlation, 0.4 to 0.69 representing moderate correlation, 0.7 to 0.89 representing strong correlation, and >0.9 representing very strong correlation.17 In addition, we used a Bland–Altman plot to display the individual data points as well as the mean difference between the 2 methods. In this plot, the differences between the 2 methods for a given urinary biomarker are used in the y-axis, whereas the average of those measurements is used in the x-axis. For each urinary biomarker, the mean difference, or bias, along the 95% limits of agreement will be displayed.18 In addition, the percentage of values within the 95% limits of agreement will be reported.

Finally, using ELISA methodology, a modified RAIL score was created using only 4 biomarkers. Taking hemopexin and ceruloplasmin to 0, the modified RAIL score formula was as follows: \[-5.05 - 0.56\times\text{NGAL} + 0.12\times\text{MCP-1} + 0.88\times\text{Adiponectin} - 0.02\times\text{KIM-1}. \]

The agreement between this modified RAIL score and the original RAIL score were evaluated using an ICC. All urine biomarker levels are reported after natural log transformation to normalize their distribution when considered in the RAIL or in the presented analyses, as previously described.9 The clinical status of the patients were blinded to the performers of the ELISA and MPL assays, but status was unblinded for analysis. Statistical analyses were performed using R Foundation for Statistical Computing software, version 4.0.2.

**RESULTS**

**Patients and Samples**

Flow of participants are shown in supplementary Figure S1. There were 46 patients, amounting to 341 samples. Because of inadequate standard curve creation with 1 ELISA run for adiponectin, 50 samples were excluded in the adiponectin and RAIL analysis, resulting in a total of 291 samples included for that assessment of method agreement.

Overall patient characteristics are shown in Table 1, also stratified by BILAG score. The average age of the patients was 41 years, ranging from 20 to 73 years, and 61% (28/46) of the patients were female. We lacked clinical information from 11 patients, amounting to 159 samples; however they were not excluded from the analysis. Overall, the patients had normal renal function, with an average glomerular filtration rate (GFR) of 96.5 ml/min per 1.73 m2. The majority of patients lacked active LN; as such, 113 of 341 patients (33%) had a Renal BILAG score of D, and 39 of 341 patients (11.44%) had a Renal BILAG score of E. The samples from patients with higher BILAG scores (A, B) still had normal renal function with average GFR 92.80 and 99.13 ml/min per 1.73 m2, respectively. This group had mild proteinuria, with average urine-to-protein ratio (UPCr) of 1.05 mg/mg and 0.45 mg/mg, respectively. Even in the patients with clinically active renal disease, the average RAIL score by ELISA was −6.73 (BILAG A) and −6.41 (BILAG B), that is, well below the cutoff for
Table 1. Patient characteristics (N = 341)

|                | A         | B         | C         | D         | E         | N/A        | P value |
|----------------|-----------|-----------|-----------|-----------|-----------|------------|---------|
|                | n = 2     | n = 25    | n = 3     | n = 113   | n = 39    | n = 159    |         |
|                | (0.6%)    | (7.33%)   | (0.9%)    | (33%)     | (11.44%)  | (46.63%)   |         |
| GFR, ml/min per 1.73 m², mean (SD) | 96.52 (20.88) | 92.80 (0) | 99.13 (23.97) | 87.30 (7.45) | 96.46 (23.12) | 98.81 (10.71) | 0.776   |
| UPCR, mg/mg, mean (SD) | 0.17 (0.18) | 1.05 (0)  | 0.45 (0.21) | 0.46 (0.04) | 0.12 (0.06) | 0.08 (0.07) | 2 x 10⁻¹⁶|
| dsDNA, IU/ml, mean (SD) | 124.48 (168.74) | 57.00 (0) | 371.72 (271.26) | 185.00 (39.84) | 80.65 (96.12) | 91.79 (119.49) | 8.14 x 10⁻¹⁶|
| C3, mg/dl, mean (SD) | 91.65 (36.61) | 38.00 (0) | 73.38 (17.23) | 40.13 (13.57) | 99.47 (35.58) | 87.41 (40.93) | 0.000115|
| C4, mg/dl, mean (SD) | 18.13 (10.28) | 5.00 (0)  | 13.50 (4.71) | 9.40 (4.33) | 17.55 (10.16) | 24.13 (10.86) | 4.07 x 10⁻⁶ |
| Complete RAIL score (by ELISA); mean (SD) | -6.81 (1.22) | -6.73 (0.96) | -6.41 (1.12) | -5.82 (0.43) | -6.75 (1.20) | -7.17 (1.24) | 0.135   |

ELISA, enzyme-linked immunosorbent assay; GFR, glomerular filtration rate; RAIL, Renal Activity Score for Lupus; UPCr, urine-to-protein ratio.

Table 2. Biomarker mean results by BILAG class (N = 341)

| Biomarker          | A (n = 2)    | B (n = 25)   | C (n = 3)    | D (n = 113)   | E (n = 39)    | N/A (n = 159)     | P value |
|--------------------|--------------|--------------|--------------|---------------|---------------|-------------------|---------|
| NGAL, ng/ml, mean (SD) | 2.66 (1.98)  | 4.03 (1.22)  | 1.67 (2.03)  | 2.84 (1.37)   | 3.52 (1.45)   | 2.80 (1.41)       | 0.00016 |
| ELISA              | 2.15 (0.93)  | 2.54 (0.47)  | 1.60 (1.24)  | 2.20 (0.82)   | 3.52 (0.57)   | 2.33 (1.00)       | 0.232   |
| MPL                | 5.78 (0.78)  | 6.75 (0.71)  | 6.13 (0.48)  | 5.87 (1.78)   | 6.19 (1.10)   | 6.24 (1.15)       | 0.00689 |
| KIM-1, pg/ml, mean (SD) | 5.78 (1.02)  | 6.62 (0.67)  | 5.95 (0.63)  | 5.97 (1.35)   | 5.99 (1.20)   | 6.30 (0.99)       | 0.01    |
| ELISA              | 5.78 (0.78)  | 6.75 (0.71)  | 6.13 (0.48)  | 5.87 (1.78)   | 6.19 (1.10)   | 6.24 (1.15)       |         |
| MPL                | 5.53 (0.53)  | 5.47 (0.75)  | 4.69 (0.65)  | 4.60 (1.73)   | 4.89 (2.00)   | 5.20 (0.96)       | 0.00231 |
| MCP-1, pg/ml, mean (SD) | 5.26 (1.04)  | 5.48 (0.74)  | 4.89 (0.81)  | 4.60 (1.90)   | 4.75 (1.33)   | 5.14 (0.93)       | 0.00978 |
| ELISA              | 1.71 (0.10)  | 1.69 (0.18)  | 1.53 (0.17)  | 1.55 (0.31)   | 1.56 (0.26)   | 1.63 (0.23)       | 0.0609  |
| MPL                | 1.54 (0.82)  | 4.11 (0.59)  | 2.88 (0.61)  | 2.49 (1.35)   | 2.78 (0.99)   | 2.27 (1.44)       | 7.05 x 10⁻⁶ |
| Adiponectin, ng/ml, mean (SD) | 8.80 (4.01)  | 8.58 (1.05)  | 7.34 (0.16)  | 6.77 (1.09)   | 6.80 (1.02)   | 7.06 (0.86)       | 1.44 x 10⁻¹³ |
| ELISA              | 6.23 (1.87)  | 7.21 (0.42)  | 6.51 (0.47)  | 5.91 (1.06)   | 5.85 (1.01)   | 6.29 (0.94)       | 6.54 x 10⁻⁸ |
| Ceruloplasmin, ng/ml, mean (SD) | 8.80 (4.01)  | 6.23 (1.87)  | 7.21 (0.42)  | 6.51 (0.47)   | 5.91 (1.06)   | 5.85 (1.01)       | 6.29 (0.94) |
| Hemopexin, ng/ml, mean (SD) | 8.80 (4.01)  | 6.23 (1.87)  | 7.21 (0.42)  | 6.51 (0.47)   | 5.91 (1.06)   | 5.85 (1.01)       | 6.29 (0.94) |

BILAG, British Isles Lupus Assessment Group; ELISA, enzyme-linked immunosorbent assay; KIM-1, kidney injury molecule–1; MCP-1, monocyte chemoattractant protein–1; MPL, multiplex platform; NGAL, neutrophil gelatinase–associated lipocalin.
0.047 (95% CI = −0.03 to 0.12), and 97% of values were within the 95% limits of agreement.

Table 3. Intraclass correlation coefficient (ICC) values

| Biomarker                      | R = ICC | 95% Lower CL | 95% Upper CL |
|-------------------------------|---------|--------------|--------------|
| NGAL                          | 0.69    | 0.63         | 0.74         |
| KIM-1                         | 0.86    | 0.83         | 0.88         |
| MCP-1                         | 0.93    | 0.91         | 0.94         |
| Adiponectin                   | 0.78    | 0.74         | 0.82         |
| Modified versus original RAIL | 0.68    | 0.62         | 0.74         |
| Original RAIL MPL versus ELISA| 0.97    | 0.96         | 0.98         |

CL, confidence limit; ELISA, enzyme-linked immunosorbent assay; KIM-1, kidney injury molecule 1; MCP-1, monocyte chemoattractant protein 1; MPL, multiplex platform; NGAL, neutrophil gelatinase–associated lipocalin; RAIL, Renal Activity Score for Lupus.

MCP-1

MCP-1, measured in picograms per milliliter (pg/ml), ranged from −0.65 to 7.79 (mean ± SD = 4.99 ± 1.31 pg/ml) by ELISA and −1.35 to 8.16 (mean ± SD = 4.94 ± 1.39 pg/ml) when using the MPL assay. The ICC was 0.93 (95% CI = 0.91–0.94) (Table 3), supporting excellent agreement between the 2 tests. The scatter plot and Bland–Altman plots are shown in Figure 3a and b. Overall, MCP-1 demonstrated very strong correlation throughout the multiplex detection range (Figure 3a). There was minimal difference between the 2 tests, as shown by the Bland–Altman (Figure 3b), with a mean difference of 0.046 (95% CI = −0.01 to

Figure 1. (a) Neutrophil gelatinase–associated lipocalin (NGAL) scatter plot. Comparison of enzyme-linked immunosorbent assay (ELISA) and multiplex for NGAL, with R value of 0.78. (b) NGAL Bland–Altman plot. Mean difference of 0.669, denoted by central line (95% confidence interval = 0.57–0.77). In all, 96% of differences will be between −1.17 and 2.50 (the 95% limit of agreement denoted by lines).
0.1), and 96% of values were within the 95% limits of agreement.

Adiponectin

Adiponectin levels (in nanograms per milliliter [ng/ml]) by ELISA ranged from 1.05 to 5.37 (mean ± SD = 1.61 ± 0.26 ng/ml) and from 3.36 to 5.24 (mean ± SD = 2.54 ± 1.41 ng/ml) when using the MPL assay. The ICC was 0.78 (95% CI = 0.74–0.82) (Table 3), supporting good agreement between the 2 tests. Overall, adiponectin demonstrated strong correlation throughout the multiplex detection range, although there is evidence of a flooring effect for the MLP assay to capture the lower end of the ELISA range (as shown in Figure 4a).

There was some negative bias as shown by the Bland—Altman (Figure 4b), with a negative mean difference of −0.87 (95% CI = −0.97 to −0.77), suggesting that the multiplex assay values were consistently higher than the ELISA assay values and that 96% of the values were within the 95% limits of agreement.

Modified RAIL Score ELISA Versus Multiplex

The RAIL scores were then calculated using the formula listed above, using NGAL, KIM-1, MCP-1, and adiponectin. A total of 291 samples were included in this analysis. The Modified RAIL scores using the ELISA ranged from −9.562 to −1.742 (mean ± SD = −4.82 ±

---

**Figure 2.** (a) Kidney injury molecule–1 (KIM-1) scatter plot. Comparison of enzyme-linked immunosorbent assay (ELISA) and multiplex for KIM-1, with R value of 0.87. (b) KIM-1 Bland—Altman plot. Mean difference of 0.047, denoted by central line with 95% confidence interval −0.03 to 0.12. In all, 97% of differences will be between −1.28 and 1.38 (the 95% limit of agreement denoted dashed lines).
The Modified RAIL scores using the MPL assay ranged from −8.776 to −1.056 (mean ± SD = −3.64 ± 1.15). The ICC was 0.68 (95% CI = 0.62–0.74) (Table 3), supporting good consistency between the 2 tests. As shown in Figure 5a and b, the comparison of the modified RAIL score via ELISA versus MPL using only 4 urinary biomarkers demonstrated good correlation (R = 0.65; P = 2 × 10^{−16}). Of note, variability between the modified RAIL scores (ELISA, MPL) tended to increase toward the negative end range of the scales (Figure 5a). There was a mean difference of −1.14 per the Bland–Altman (Figure 5b), suggesting a consistently lower measurement by ELISA compared to MPL. Finally, about 95% of values calculated by Bland–Altman fell between the 95% limits of agreement lines.

**Modified Versus Original RAIL Score**

Finally, using the ELISA results, RAIL scores using the biomarkers for which the MPL bead assay was successful (NGAL, KIM-1, MCP-1, and adiponectin), were calculated and compared to the original RAIL scores, using all 6 biomarkers (NGAL, KIM-1, MCP-1, adiponectin, hemopexin, and ceruloplasmin). As shown in Figure 6a, the Modified RAIL score ranged from −9.562 to −1.742 (mean ± SD = −4.82 ± 1.26). The original RAIL score ranged from −12.01 to −3.831 (mean ±
The ICC was excellent at 0.97 (95% CI = 0.96–0.98) (Table 3). The regression correlation coefficient was 0.97, suggesting excellent correlation between a RAIL score based on only 4 urinary biomarkers and the original RAIL score based on all 6 biomarkers. On Bland–Altman analysis (Figure 6b), the modified RAIL score exhibited a higher value of ~2 (based on a mean difference of 1.98), consistent with the absence of 2 biomarkers in the formula. In all, 96% of mean differences will be between −2.59 and 0.85 (the 95% limits of agreement denoted by dashed lines).

**DISCUSSION**

We report a high level of congruency among 4 of the 6 urine biomarkers considered in the RAIL when assayed on the LUMINEX platform as opposed to ELISAs. Considering only the 4 RAIL biomarkers that we successfully multiplexed, the RAIL scores of the 2 modalities had an ICC of 0.784, supporting good agreement between the 2 tests. Furthermore, the ICC between the modified RAIL with 4 biomarkers (NGAL, KIM-1, MCP-1, and adiponectin) and original RAIL with 6 biomarkers was excellent, at 0.97. With this reliability between the multiplex assay and ELISA, the RAIL score will be more clinically accessible and with a reasonable turnaround time to make clinical decisions. This raises the possibility that a modified RAIL score could suffice to identify LN activity over time. Further research is needed to evaluate the ability of this modified

![Figure 4](image-url)
RAIL score to predict high renal inflammation on kidney biopsy. However, these preliminary data are promising, as the modified RAIL score appears to be a robust tool to use RAIL testing in daily clinical practice.

There continues to be intensive research in urinary biomarkers for kidney disease, given the inadequacy of current markers, both in lupus and in other diseases.\(^7,^{19-21}\) As shown by Devarajan et al., serum creatinine was a problematic and often inaccurate measure of renal injury, and urine NGAL was introduced as a biologically appropriate marker of injury.\(^22\)

It has since been instituted clinically, successfully detecting acute kidney injury (AKI) prior to increase in serum creatinine. Of particular importance, the test is point of care, allowing it to be run rapidly to ensure clinical utility.\(^23\) Tengstrand et al. performed multiplexed assay for urinary biomarkers in drug-induced kidney injury in rats. Their biomarkers including KIM-1 and NGAL, among others. They found the multiplexed assays efficient to quantify the biomarkers, saving time and costs with overall analysis. Future directions would be working toward configuring the panel toward human analysis.\(^19\)

Urinary biomarkers in LN specifically are also an active field of study. Landolt-Marticorena et al.
published on urinary biomarkers distinguishing active
LN patients and patients with SLE without nephritis,
which were identified using multiplex technology and
had excellent correlation with biopsy activity. Their
panel included NGAL, MCP-1, KIM-1, and adiponectin,
but did not include hemopexin or ceruloplasmin. They
did note that some of their samples had biomarkers that
outperformed the same biomarkers in other studies that
used ELISA but did not attribute it to the multiplex
system. Smith et al. have also proposed urinary
biomarker panel measured by ELISA with excellent
predictive ability of kidney histopathology. However,
the group acknowledges the need for further validation
as well as the need to transition to point-of-care testing
for their biomarkers.

There were several limitations to this study. First, it
was limited by the number of patients with severe LN,
in whom the RAIL score has been validated. In addi-
tion, there were no histological data available for
comparison of the clinical renal disease activity. When
comparing the RAIL score on the 2 different platforms,
more differences are noted in the more negative range,
when patients do not have renal disease or do not have
active renal disease. Given this, it likely does not hold
much clinical significance, but will require further
study. Next, the samples were run on the respective

Figure 6. (a) Scatter plot comparison of modified versus original Renal Activity Score for Lupus (RAIL) score. RAIL scores calculated with 4 (excludes hemopexin and ceruloplasmin) versus 6 urinary biomarkers via enzyme-linked immunosorbent assay (ELISA) methodology, with R value of 0.97. (b) ELISA Bland–Altman Plot. Comparison of modified versus original RAIL score. RAIL scores calculated with 4 (excludes hemopexin and ceruloplasmin) versus 6 urinary biomarkers via ELISA methodology. Mean difference of 1.98, denoted by dashed line (95% confidence interval = 1.95–2.2). In all, 94% of the values fell between 1.37 and 2.59 (the 95% limits of agreement denoted by the dashed lines).
platforms at 2 different time points. Stability of the urinary biomarkers in the RAIL formula was previously established, but there was note of minimal degradation of the proteins over time.\textsuperscript{27} The ELISA samples were run first, followed by multiplex assay, and it is unclear whether this led to some of the bias seen, particularly with NGAL and adiponectin. With NGAL, there also appeared to be dilutional factors needed for the multiplex modality, particularly when ELISA detected NGAL >500 ng/ml. For NGAL multiplex, the minimum detection was 17 to 63.1 pg/ml, with no specific upper limit of detection listed on the manufacturer’s website. Further evaluation will be required the assess the MPL’s ability to detect NGAL in high quantities in the urine.

This study holds promise in the feasibility of using the multiplex platform to calculate the RAIL score. Future directions include repeating the multiplex assays in a new cohort of patients, particularly those with active renal inflammation. In addition, further assessment is needed with the modified RAIL score to assess its ability in detecting high renal inflammation to determine whether it is an acceptable replacement for the original formula. Correlating with clinical parameters will help finalize the preparation of RAIL for clinical use.

**DISCLOSURE**

HIB, MB, and PD are co-inventors on patents submitted for the use of RAIL biomarkers in lupus nephritis. HIB: Speaking fees for Novartis and Roche (both >$10,000) and GlaxoSmithKline (<$10,000); Consultancies/honoraria (<$10,000): AbbVie, Astra Zeneca-Medimmune, Biogen, Boehringer, Bristol-Myers Squibb, Celgene, Eli Lilly, EMD Serono, Genzyme, GlaxoSmithKline, F. Hoffmann-La Roche, Merck, Novartis, R-Pharm, Sanofi. The Cincinnati Children’s Hospital, where HBR works as a full-time public employee, has received contributions (>10,000 each) from the following industries in the past 3 years: Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, F. Hoffmann-La Roche, Janssen, Novartis, and Pfizer. This funding has been reinvested for the research activities of the hospital in a fully independent manner, without any commitment to third parties. HIB’s time is supported by supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (grant P30-AR-076316). This work was funded by an Innovation Award from the Cincinnati Children’s research Foundation awarded jointly to PD and HIB. All the other authors declare no competing interests.

**ACKNOWLEDGMENTS**

Support was provided by the CCHMC Innovation Fund, Support PORTICO, and Lupus Foundation of America (LFA). HIB is supported by the National Institutes of Arthritis and Musculoskeletal Skin Diseases (NIH) under Award Number P30AR076316. PD is supported by a grant from the NIDDK (P50 DK096418). We are grateful for the support and samples provided by MedImmune to complete this project. We are also grateful for the support of the NIAMS Cincinnati Rheumatology Core Center Biobank (P30AR070549; Susan Thompson PI) and its assistance of sample storage. This work was completed in partial fulfillment of the Master of Science degree in Clinical and Translational Research in the Division of Epidemiology, University of Cincinnati College of Medicine by EMC.

**SUPPLEMENTARY MATERIAL**

Supplementary File (PDF)

Figure S1. Flow chart for patient and sample inclusion.

**REFERENCES**

1. Parikh SV, Almaani S, Brodsky S, et al. Update on lupus nephritis: core curriculum 2020. *Am J Kidney Dis*. 2020;76:265–281.
2. Tektonidou MG, Dasgupta A, Ward MM. Risk of end-stage renal disease in patients with lupus nephritis, 1971–2015: a systematic review and Bayesian meta-analysis. *Arthritis Rheumatol*. 2016;68:1432–1441.
3. Almaani S, Meara A, Rovin BH. Update on lupus nephritis. *Clin J Am Soc Nephrol*. 2017;12:825–835.
4. Borgia RE, Silverman ED. Childhood-onset systemic lupus erythematosus: an update. *Curr Opin Rheumatol*. 2015;27:483–492.
5. Malvar A, Pirruccio P, Alberton V, et al. Histologic versus clinical remission in proliferative lupus nephritis. *Nephrol Dial Transplant*. 2017;32:1338–1344.
6. Rovin BH, Zhang X. Biomarkers for lupus nephritis: the quest continues. *Clin J Am Soc Nephrol*. 2009;4:1858–1865.
7. Mina R, Abulaban K, Klein-Gitelman M, et al. Validation of the Lupus Nephritis Clinical Indices in Childhood-Onset Systemic Lupus Erythematosus. *Arthritis Care Res (Hoboken)*. 2016;68:195–202.
8. Anders HJ, Rovin B. A pathophysiology-based approach to the diagnosis and treatment of lupus nephritis. *Kidney Int*. 2016;90:493–501.
9. Brunner HI, Michael B, Abulaban K, et al. Development of a novel renal activity index of lupus nephritis in children and young adults. *Arthritis Care Res (Hoboken)*. 2016;68:1003–1011.
10. Gulati G, Bennet M, Abulaban K, et al. Prospective validation of a novel renal activity index of lupus nephritis. *Lupus*. 2017;26:927–936.
11. Brunner HI, Bennet M, Gulati G, et al. Urine biomarkers to predict response to lupus nephritis therapy in children and young adults. *J Rheumatol*. 2017;44:1239–1248.
12. Graham H, Chandler DJ, Dunbar SA. The genesis and evolution of bead-based multiplexing. *Methods*. 2019;158:2–11.
13. Ellington AA, Kullo I, Bailey K, et al. Antibody-based protein multiplex platforms: technical and operational challenges. *Clin Chem*. 2010;56:186–193.
erythematosus: British Isles Lupus Assessment Group (BILAG), European Consensus Lupus Activity Measurement (ECLAM), Systemic Lupus Activity Measure (SLAM), Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), Physician’s Global Assessment of Disease Activity (MD Global), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SLICC/ACR DI; SDI). Arthritis Care Res (Hoboken). 2011;63(Suppl 11):S112–S117.
15. Chaturvedi S, Farmer T, Kapke GF. Assay validation for KIM-1: human urinary renal dysfunction biomarker. Int J Biol Sci. 2009;5:128–134.
16. Koo TK, Li MY. A Guideline of selecting and reporting intra-class correlation coefficients for reliability research. J Chiropr Med. 2016;15:155–163.
17. Schober P, Boer C, Schwarte LA. Correlation coefficients: appropriate use and interpretation. Anesth Analg. 2018;126:1763–1768.
18. Chhapola V, Kanwal SK, Brar R. Reporting standards for Bland-Altman agreement analysis in laboratory research: a cross-sectional survey of current practice. Ann Clin Biochem. 2015;52:382–386.
19. Tengstrand E, Zhang H, Liu N, et al. A multiplexed UPLC-MS/MS assay for the simultaneous measurement of urinary safety biomarkers of drug-induced kidney injury and phospholipidosis. Toxicol Appl Pharmacol. 2019;366:54–63.
20. Andreucci M, Faga T, Pisani A, et al. The ischemic/nephro-toxic acute kidney injury and the use of renal biomarkers in clinical practice. Eur J Intern Med. 2017;38:1–8.
21. Bennett M, Brunner HI. Biomarkers and updates on pediatrics lupus nephritis. Rheum Dis Clin North Am. 2013;39:833–853.
22. Desanti De Oliveira B, Xu K, Shen T, et al. Molecular nephrology: types of acute tubular injury. Nat Rev Nephrol. 2019;15:599–612.
23. Roy JP, Forster CS. Clinical progress note: pediatric acute kidney injury. J Hosp Med. 2019;14.
24. Landolt-Marticorena C, Prokopec S, Morrison S, et al. A discrete cluster of urinary biomarkers discriminate between active systemic lupus erythematosus patients with and without glomerulonephritis. Arthritis Res Ther. 2016;18:218.
25. Smith EM, Jorgensen A, Midgley A, et al. International validation of a urinary biomarker panel for identification of active lupus nephritis in children. Pediatr Nephrol. 2017;32:283–295.
26. Smith EMD, Lewandowski L, Jorgensen A, et al. Growing international evidence for urinary biomarker panels identifying lupus nephritis in children—verification within the South African Paediatric Lupus Cohort. Lupus. 2018;27:2190–2199.
27. Schuh MP, Nehus E, Ma Q, et al. Long-term stability of urinary biomarkers of acute kidney injury in children. Am J Kidney Dis. 2016;67:56–61.